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Vaginal microbicides for preventing mother-to-child 
transmission of HIV infection - no evidence of an effect or 
evidence of no effect? 
Charles Shey Wiysonge, Muki Shehu Shey, Judith Shang, Eugene J Kongnyuy, Peter Brocklehurst 
Background. Vaginal disinfection is a simple, potentially 
effective strategy for reducing mother-to-child transmission 
(MTCT) of HfV that can be implemented in combination 
with antiretroviraltherapy or even in the absence of prenatal 
HfV testing. We systematically reviewed currently available 
randomised controlled trials to estimate the benefits and risks 
of this intervention. 
Methods. '\rVe conducted an exhaustive search for published and. 
unpublished trials the effect of microbicides 
on.MTCT of HIV, extracteq data in triplicate, as1>es!;eo 
statistical heterogeneity between trial results, and conducted 
meta-analysis using Mantel-Haenszel's method. 
Five potentially. eligible studies were iclentified, two 
met eligibility criteria. Pooling the data shows that 
effect of vaginal disinfection on the risk of MTCT of HIV 
risk (RR) 0.94, 95% confidence interval (CI) 0.71 1.25) 
Nearly 2 000 children under the age of 15 are infected with the 
human immunodeficiency virus (HIV) each day in low- and 
middle-income countries.1 These children acquire HIV infection 
primarily through mother-to-child transmission (MTCT), the 
risk (without intervention) of which ranges from 15 30% in 
Europe and North America to 30 - 45% in sub-Saharan Africa.2 
Childhood illness and death resulting from HIV infection 
may seriously undermine successful child survival 
programmes, which have been promoted and supported 
by the international community over the years.3 Together 
with the rising cost of comprehensive health care to treat 
HIV infection and AIDS, this has led to the development 
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ai1,d neonatal death (RR 1.36, CI 0.32- 5.79) is uncertain. 
The combined data (two trials with 708 participants) had less 
than 80% power to detect a 30% reduction in the risk of MTCT 
of HIV from a baseline risk of 30%, and are compatible with a 
widerange of effects; from a 29% reduction to a 25% increase 
in risk. One with 108 participants, showed no evidence 
that adverse effects increased inmothers (RR L02, 95% CI 0.87-
1.20} and found that adverse effects decreased in neonates (RR 
0.45, 95% CI 0.32 - 0.64). 
interpretation. At present there is insufficient and inconclusive 
evidence on the effect of vaginal microbicides on the risk of 
MTCT of HIV. This review identifies the need and provides 
the impetus for an adequately powered randomised controlled 
trial to assess the effect(s) of this inexpensive intervention. 
$ Afr Med {2007; 97: 530·533. 
of numerous to prevent MTCT of !HV.2 Despite 
the benefits of antiretroviral therapyY the costs associated 
with these interventions, their complexity, and the need for 
skilled personnel limit their availability in low- and middle-
income countries, where most of the MTCT of HIV takes 
In addition, the majority of infected women in these 
countries are not aware of their HIV infection status.6 Simple, 
inexpensive, and effective interventions that could potentially 
be implemented in the absence of prenatal HIV 
programmes would be valuable. 
In the absence of breastfeeding, most infant HIV infections 
occur during labour and delivery/In addition, studies of twins 
indicate that first-born infants have a risk of infection at least 
twice that of second-born infants.8•9 These observational data 
suggest that exposure might be an important route 
of infection, a hypothesis supported by the protective effect 
of caesarean delivery.10 Disinfection of the birth canal during 
pregnancy and labour is therefore a potential low-cost strategy 
for reducing MTCT of HIV infection. 
\.Ve conducted a systematic review of randomised controlled 
trials comparing vaginal disinfection with an appropriate 
control group conducted to date, to estimate the effect of 
vaginal disinfection on the risk of MTCT of HIV infection and 
infant mortality, and the safety of the intervention. Although 
the key to prevention of MTCT of HIV is primary prevention of 
HIV infection in women, prevention of HIV transmission from 
ORIGINAL ARTICLES 
an infected mother to her child requires as much attention. The 
ultimate goal of this systematic review is to determine whether 
the use of vaginal microbicides during pregnancy and labour 
could be recommended as a public health policy to reduce 
MTCT of HIV infection and, as such, we have considered 
overall HIV infection in the child without differentiating 
between antenatal, intrapartum and postnatal infection. 
Methods 
Search strategy 
We searched the following electronic databases for randomised 
trials published between 1980 and April2006: Cochrane 
Central Register of Controlled Trials (CENTRAL), PubMed, 
EMBASE, and AIDSearch, by combining terms for the 
intervention (benzalkonium, betadine, chlorhexidine, 'vaginal 
antisept* -creams-foams-gel-jellies-OR-tablet*', 'vaginal 
cleansing-disinfection-OR-wash') and the health condition 
(pregnancy, !abo*, birth, intrapartum, delivery). Standardised 
methodological filters for identifying controlled trials were 
applied,11 as appropriate. We supplemented the search by 
searching reference lists of identified articles and abstracts 
presented by April2006 at the International Conference on 
AIDS, the Conference on Retroviruses and Opportunistic 
Infections, and the Conference on Global Strategies for the 
Prevention of HIV Transmission From Mothers to Infants. For 
unpublished data and ongoing trials, we contacted current 
researchers and key agencies, organisations, and academic 
centres. Relevant editorials, expert opinions, and letters to the 
editor were also scrutinised for any additional relevant studies 
or unpublished data. There were no language restrictions to 
our search. 
Study selection and characteristics 
We included only randomised controlled trials, defined as a 
study in which the participants were assigned prospectively 
to one of two or more interventions by random allocation. 
Participants included were known HIV-infected women (as 
diagnosed by an antibody test) of any age and clinical stage of 
HIV disease, during labour and delivery. Trials assessing the 
effect of vaginal disinfection on adverse birth outcomes for 
HIV-negative women or those of unknown HIV status were not 
included in this review. The primary outcome measure was 
the HIV infection status of the child. The secondary outcome 
measures were neonatal mortality, death of the child after the 
neonatal period, and side-effects of vaginal disinfection in the 
mother and the neonate. 
Data extraction and synthesis 
We used the standard methods of the Cochrane HIV I AIDS 
Group (http:/ /www.igh.org/Cochrane) to prepare the 
protocol, apply inclusion criteria, assess quality, and extract 
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data. Quality assessment was based on the adequacy of 
allocation concealment, generation of allocation sequence, and 
blinding of study participants, investigators, and outcome 
assessors. Two authors (CSW and MSS) conducted the search 
with the assistance of the Cochrane HIV I AIDS Trial Search 
Coordinator and the rest of the reviewers were informed of 
its progress. Three authors (CSW, MSS and PB) independently 
assessed eligibility and quality, and extracted data on relevant 
outcome measures using a standardised data abstraction form. 
Disagreements were resolved by discussion. If a disagreement 
were to persist, the other authors would have arbitrated. 
We expressed study results as relative risks (RR) with 95% 
confidence intervals (CI) and assessed statistical heterogeneity 
using the x2-test of homogeneity, with a p-value,; 0.1 indicating 
significance. There was no significant heterogeneity between 
the two included studies (F = 0%, p = 0.94), and we pooled the 
study results using Mantel-Haenszel's fixed effect methodY 
We planned to use meta-regression to explore the effect of 
trial quality and other trial characteristics13 on estimated 
treatment effects, but the number of trials was not sufficient 
for this type of analysis. No subgroup analyses based on 
patient characteristics were planned a priori, as these are better 
investigated using individual patient data meta-analysis. 
Role of the funding source 
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of the 
report. The corresponding author had full access to all the data 
in the study and had final responsibility for the decision to 
submit this manuscript for publication. 
Results 
Description and quality of included studies 
Fig. 1 summarises the search and selection of identified 
studies. Of the five potentially relevant studies,l4-20 two18•19 were 
included in this review. In one of the included studies, Gaillard 
et al. 21 allocated HIV-infected pregnant women in labour in 
Mombasa, Kenya, to either vaginal irrigation with 120 ml 
chlorhexidine (0.2% at the beginning and 0.4% towards the 
end of the trial) or no intervention, in alternating weeks. This 
approach to the generation of allocation sequence is inadequate 
and this trial is therefore considered of low quality. Women 
who delivered within 1 hour of admission, those in whom 
the time between first irrigation and delivery was less than 1 
hour, and those for whom the time between the last irrigation 
and delivery was more than 4 hours, were excluded from the 
analysis. 
There was adequate allocation concealment in the second 
trial, in which Mandelbrot et al. 19 randomly assigned HIV-
infected pregnant women in Cote d'Ivoire and Burkina 
Faso to either 1% benzalkonium chloride or placebo using a 
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Potentially relevant publications identified and evaluated for inclusion (N = 9) 
Excluded (N = 7): 
Sub-study of eligible trials (N = 4) 
Pilot study (N 2) 
Non-randomised design (N = 1) 
Trials fulfilling eligibility criteria and included in systematic review (N 2) 
Trials included in the quantitative data syntheses by outcome measure 
I 
I 
Infant HIV status (N = 2) Safety (N 1) Neonatal and infant death (N = 1) 
Fig.l. Flow chart rarrdmnis,ea controlled trials 
computer-generated system by block-randomisation. Women 
self-administered the vaginal capsules daily from 36 weeks 
of pregnancy until labour. Another vaginal capsule was 
administered at the of the delivery process in the 
maternity ward, under of the study team. Finally, 
the neonate was bathed in either 1% solution of benzalkonium 
chloride or placebo within 30 minutes of delivery, in the 
delivery room. However, this trial was considerably 
underpowered to find a difference in transmission rates 
between treatment arms as it was designed as a phase Il trial 
to evaluate the tolerability and acceptability of benzalkonium 
chloride, not its efficacy. 
Quantitative data synthesis 
Pooling the data from the two included trials 2) with a 
total of 708 participants20,21 shows no evidence of an effect of 
vaginal disinfection on the risk of MTCT of HIV (RR 0.94, 95% 
CI 0.71 - 1.25), neonatal death (RR 1.36, 95% CI 0.32 5.79), or 
death after the neonatal period (RR 1.39, 95% CI 0.52 3.71). 
The combined data have 78% power to detect a 30% 
reduction in the risk of MTCT of HIV from a baseline risk of 
30%, and are compatible with a wide range of effects, from a 
29% reduction in risk to a 25% increase. One trial, with HJ8 
participants, showed no evidence that adverse effects increased 
in mothers (RR 1.02, 95% CI 0.87 1.20) and found that adverse 
effects decreased in neonates (RR 0.4.'5, 95% Cl 0.32- 0.64). 
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Discussion 
We found no evidence of an effect of vaginal microbicides 
on the risk of "viTCT of HIV infection and infant mortality. 
However, the of randomised controlled trials 
evaluating the effect of vaginal disinfection during labour on 
MTCT of HIV means that the database has limitations. The 
two included trials were considerably underpowered to find a 
significant difference in MTCT rates between treatment arms. 
Given the magnitude of the paediatric HIV epidemic in low-
and middle-income countries of the world,1 the suggestion that 
vaginal exposure might increase the risk of MTCT of 
and the need for cheap, safe, and easy interventions to be used 
alone or in association with a short course of antiretroviral 
therapy,5 there is need for adequately powered 
randomised controlled trials to the effect of vaginal 
microbicides on MTCT of HIV, or more likely, the additive 
effect of microbicides in antiretroviraHreated women. 
Implications for practice 
At the moment, there is no high-quality evidence to develop 
practice guidelines for use of vaginal microbicides to reduce 
the risk of MTCT of HIV infection. 
Implications for research 
There is a need for adequately powered 
randomised controlled trials to estimate the effect of 
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favours microbicide Favours placebo 
microbicides on the risk of MTCT of HIV infection. Ethically, 
women in either arm of such trials should be provided a short 
course of antiretroviral therapy. 
CSW and PB conceived the study, CSW, MSS, and PB did data 
extraction, CSW and MSS conducted the analysis, and all authors 
participated in the interpretation of the data. CSW wrote the first 
draft of the paper and all the authors contributed intellectually to 
and approved the final version. The authors have no conflict of 
interest. 
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